| First Author | Adachi T | Year | 2002 |
| Journal | J Toxicol Sci | Volume | 27 |
| Issue | 3 | Pages | 147-63 |
| PubMed ID | 12238139 | Mgi Jnum | J:79063 |
| Mgi Id | MGI:2387061 | Doi | 10.2131/jts.27.147 |
| Citation | Adachi T, et al. (2002) Twenty-six week carcinogenicity study of ampicillin in CB6F1-TgrasH2 mice. J Toxicol Sci 27(3):147-63 |
| abstractText | As a part of the ILSI-HESI Alternative to Carcinogenicity Testing (ACT) program, we performed a 26-week carcinogenetic study of nonmutagenic drug, ampicillin (ABPC) in Tg-rasH2 mice. ABPC was given to Tg-rasH2 mice (0, 350, 1000, 3000 mg/kg, p.o.) and Non-Tg mice (0, 3000 mg/kg, p.o.) daily for 26 weeks. As a positive control, a single dose of MNU was administered once to Tg-rasH2 mice (75 mg/kg, i.p.). In this study, Tg-rasH2 mice did not demonstrate any increases in tumor development in response to ABPC. Thus, ABPC had no carcinogenicity in the 26-week carcinogenesis study in Tg-rasH2 mice or in a 2-year carcinogenesis study in B6C3F1 mice. |
